Vertaling van "core earnings per share " (Frans → Nederlands) :

31-oct.-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » En savoir plus
31-okt-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » meer

Les firmes devront tenir compte du Core Safety Profile agréé lors de la procédure de PSUR Work Sharing pour rédiger le résumé des caractéristiques du produit (RCP) et la notice pour le public du médicament concerné.
De firma’s moeten rekening houden met de Core Safety Profile overeengekomen in de loop van de PSUR Work Sharing procedure, bij het opstellen van de samenvatting van de kenmerken van het product (SKP) en de bijsluiter voor het publiek van het betrokken geneesmiddel.